Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
GSK and Cambridge University Announce New Five-year Collaboration in Kidney and Respiratory Disease
ViiV Reports Positive Real-world Data for HIV Prevention Drug
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
Takeda Declines to Exercise Option for Wave's WVE-003
ViiV Healthcare, Owned By GSK, Pfizer And Shionogi, Announced The Presentation Of New Real-world Evidence And Implementation Data Showing The Effectiveness, Adherence, And Quality-of-life Improvement Of Apretude (Cabotegravir Long-acting) For HIV...
The FDA Has Accepted Us Marketing Application For GSK's Gepotidacin, An Oral Antibiotic For Adult And Adolescent Females For Uncomplicated Urinary Tract Infections, 26 March 2025 Assigned As Action Date For FDA Decision
GSK's UTI Treatment Gets Accepted for Priority Review by U.S.'s FDA
ViiV Healthcare Shows More Than 99% Effectiveness in Real-world Studies for Apretude (Cabotegravir Long-acting), the Only Approved Long-acting HIV PrEP, in Data Presented at IDWeek 2024
glaxosmithkline sues Moderna for infringing its patent rights on the COVID-19 vaccine.
GlaxoSmithKline October 15th | GlaxoSmithKline filed a lawsuit against Moderna in the Federal Court of Delaware on Tuesday, alleging that Moderna's COVID-19 vaccine Spikevax infringed on its patents in mRNA technology. The company filed a similar lawsuit against Pfizer and biontech in the same court in April this year.
Express News | Glaxosmithkline Sues Moderna for U.S. Patent Infringement Over Mrna Technology in Covid-19 Vaccines - Court Filing
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Gritstone Oncology (GRTS) and Immutep (IMMP)
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK Says ANCHOR Trials for Depemokimab Met Primary Endpoints
Stocks to Watch Monday: Tesla, Boeing, Vulcan Materials, GSK -- WSJ
glaxosmithkline (GSK.US) experimental drug Depemokimab for the treatment of rhinitis trial achieved positive results
An experimental drug developed by GlaxoSmithKline for the treatment of a common type of rhinitis has shown positive results in two late-stage trials, which has boosted the research and development pipeline of this united kingdom pharmaceutical company.
GSK Respiratory Drug Shows Efficacy for Rhinosinusitis in Late-Stage Trials
GSK Announces Positive Phase III Results From ANCHOR Trials for Depemokimab in Chronic Rhinosinusitis With Nasal Polyps
GlaxoSmithKline (GSK) Gets a Hold From Kepler Capital